The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...
Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b pa ...
An announcement from Grand Pharmaceutical Group Limited ( ($HK:0512) ) is now available. Grand Pharmaceutical Group Limited has announced FDA ...
The aggregate gross proceeds to the Company from the offering were approximately $1.7 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The ...
Plasma IQ is the latest advancement in aesthetics and the first FDA Class II cleared handheld plasma device. The device delivers focused, controlled plasma energy to safely and effectively create ...
The cells of all animals—including humans—are characterized by their ability to adhere particularly well to surfaces in their ...
Background Intestinal fibrosis, a hallmark complication of Crohn’s disease (CD), frequently progresses to stricture formation ...
An in-depth look at how Turkey’s top clinics use next-generation technology to deliver superior results at globally ...
FibroBiologics files a new USPTO patent covering its fibroblast-based platform for disc repair, cartilage restoration, and ...
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback